Tel.: 514-340-8222 ext. 24365
 
Or contact:
Sabrina Nichilo
Tel.:514-340-8222 ext. 24572
email address
 
Dr. Wilson H. Miller
 
Associate Director for Clinical Research, Lady Davis Institute
Director, Clinical Research Unit, Jewish General Hospital
Director, Developmental Therapeutics, Department of Oncology, McGill University
James McGill Professor, Departments of Medicine and Oncology, McGill University
 
 
Wilson H. Miller, Jr. is the James McGill Professor in the Departments of Oncology and Medicine at McGill University, Montreal. He is Associate Director for Clinical Research of the Lady Davis Institute, and is Director of the Clinical Research Program in the Department of Oncology at McGill. Dr. Miller has a PhD from The Rockefeller University and an MD from Cornell University Medical College. He has held a faculty appointment in the Department of Medicine at Cornell and at the Memorial Sloan-Kettering Cancer Center in New York. Dr. Miller’s laboratory at the Lady Davis Institute investigates molecular mechanisms underlying leukemia and breast cancer, with a focus on the development of novel targeted therapies. He has received a number of research awards throughout his career, including the Medical Research Council of Canada Scientist Award and the FRSQ Chercheur national Award. Dr. Miller is a well-known speaker at national and international meetings and sits on peer review panels for the National Institutes of Health (US), the Canadian Institute of Health Research, the Ontario Cancer Research Network, and the Leukemia Lymphoma Society.

Major Research Activities

Dr. Miller’s laboratory uses several approaches to understand the mechanisms of action and development of novel anti-cancer therapies. Current projects include the role of nuclear co-regulators of transcription and changes in chromatin in response and resistance to epigenetic therapies in acute promyelocytic leukemia and other hematopoietic malignancies. Another area of interest for the lab is the development of novel therapeutics for breast cancer with a focus on new pathways regulating protein synthesis, modification and degradation.
 
Recent Publications

Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, Caplan S, Leber B, Roy DC,. Miller WH Jr and. Borden K. Molecular targeting of the oncogene eIF4E in AML: a proof-of-principle clinical trial with ribavirin. Blood, 114:257-260, 2009.

Stadler W M, Figlin RA, McDermott DF, Dutcher JP, . Knox JJ., Miller Jr WH, Hainsworth JD, Henderson CA, George JR, Hajdenberg J , Kindwall-Keller TL, Ernstoff MS, Drabkin HA., Curti BD., Chu L, Ryan CW, Hotte SJ., Xia C, Cupit L, Bukowski RM. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program. Cancer 2010.

Hamel S, Bouchard A, Ferrario C, Hassan S, Aguilar-Mahecha A, Buchanan M, Quenneville L, Miller WH Jr., Basik M. Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers. Breast Cancer Res Treat., 120(1):47-57, 2010.
Support research at the Lady Davis Institute - Jewish General Hospital